Congratulations to our portfolio company Thermosome. The Munich-based drug development company specializing in targeted tumor therapies announced that the first patient has been dosed in the ongoing Phase 1 trial of its lead program THE001 in April 2023.
We keep our fingers crossed for the further development of the study.
More information in the press release under the following Link
More about Thermosome
